Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

(2012) X. Liao et al.   CLINICAL CANCER RESEARCH

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

(2011) E. Calvo et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study Evaluating the Addition of Cetuximab to the Concurrent Delivery of Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients With Locally Advanced Squamous Cell Carcinomas of the Head and Neck

(2011) Mohan Suntharalingam et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

(2011) B Weigelt et al.   ONCOGENE

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

(2010) Terry OʼReilly et al.   ANTI-CANCER DRUGS

Immunosuppressant Neurotoxicity in Rat Brain Models: Oxidative Stress and Cellular Metabolism

(2010) Jelena Klawitter et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Everolimus

(2010) P. J. Houghton   CLINICAL CANCER RESEARCH

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001

(2010) Morassa Mohseni et al.   JOURNAL OF CLINICAL INVESTIGATION

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination

(2010) P. Mordant et al.   MOLECULAR CANCER THERAPEUTICS

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

(2010) Janja Ocvirk   WORLD JOURNAL OF GASTROENTEROLOGY

Optimising in vivo pharmacology studies—Practical PKPD considerations

(2010) Johan Gabrielsson et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study

(2009) Mark P. Saunders et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents

(2009) Terence O’Reilly et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors

(2009) I. Okamoto et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

(2009) Susan D. Richman et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Modeling of tumor growth and anticancer effects of combination therapy

(2009) Gilbert Koch et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Quantitative Pharmacology or Pharmacokinetic Pharmacodynamic Integration Should Be a Vital Component in Integrative Pharmacology

(2009) J. Gabrielsson et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer

(2008) P. C. Manegold et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY